| Literature DB >> 35004599 |
Yongjie Yan1, Chongyuan Chen2, Yunyu Liu3, Zuyue Zhang1, Lin Xu1, Kexue Pu1.
Abstract
Background: The etiology of fever of unknown origin (FUO) is complex and remains a major challenge for clinicians. This study aims to investigate the distribution of the etiology of classic FUO and the differences in clinical indicators in patients with different etiologies of classic FUO and to establish a machine learning (ML) model based on clinical data.Entities:
Keywords: LightGBM algorithm; etiology; fever of unknown origin; machine learning; retrospective analysis
Mesh:
Year: 2021 PMID: 35004599 PMCID: PMC8739804 DOI: 10.3389/fpubh.2021.800549
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Percentages of causes of classic FUO ranked by age.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| <20 | 13 (72.2) | 3 (16.7) | 0 (0) | 0 (0) | 2 (11.1) | 18 |
| 20–39 | 48 (47.5) | 9 (8.9) | 4 (3.9) | 7 (6.9) | 33 (32.8) | 101 |
| 40–59 | 99 (49.8) | 25 (12.6) | 12 (6.0) | 5 (2.5) | 58 (29.1) | 199 |
| ≥60 | 117 (56.0) | 14 (6.7) | 15 (7.2) | 2 (1.0) | 61 (29.1) | 209 |
| Total | 277 (52.5) | 51 (9.7) | 31 (5.9) | 14 (2.7) | 154 (29.2) | 527 |
Figure 1The relationship between the distribution of etiology and gender in patients with classic FUO.
Figure 2Etiology distribution of 527 patients with classic FUO.
Etiology distribution of 527 patients with classic FUO.
|
|
|
|
|
|---|---|---|---|
|
| 277 (52.5) |
| 2 (0.4) |
|
| 193 (36.6) | Mycoplasmal pneumonia | 2 (0.4) |
| Respiratory system infection | 116 (22.0) |
| 51 (9.7) |
| Bloodstream infection | 30 (5.7) | Hemophagocytic syndrome | 12 (2.3) |
| Urinary tract infection | 21 (4.0) | Systemic lupus erythematosus | 9 (1.7) |
| Biliary tract infection | 6 (1.1) | ANCA-associated vasculitis | 9 (1.7) |
| Liver abscess | 6 (1.1) | Adult onset still disease | 7 (1.3) |
| Cellulitis | 6 (1.1) | Sjogren syndrome | 4 (0.8) |
| Pressure ulcers infection | 2 (0.4) | Rheumatoid arthritis | 2 (0.4) |
| Reproductive tract infection | 2 (0.4) | Undifferentiated connective tissue disease | 2 (0.4) |
| Infective endocarditis | 2 (0.4) | Gouty arthritis | 1 (0.2) |
| Umbilical infection | 1 (0.2) | Dermatomyositis | 1 (0.2) |
| Intra-abdominal infection | 1 (0.2) | Takayasu arteritis | 1 (0.2) |
|
| 46 (8.7) | Crohn's disease | 1 (0.2) |
| Pulmonary tuberculosis | 35 (6.6) | Autoimmune hemolytic anemia | 1 (0.2) |
| Extrapulmonary tuberculosis | 11 (2.1) | macrophage activation syndrome | 1 (0.2) |
|
| 2 (0.4) |
| 31 (5.9) |
| Typhoid | 1 (0.2) | Lymphoma | 8 (1.5) |
| Brucellosis | 1 (0.2) | Lung carcinoma | 6 (1.1) |
|
| 21 (4.0) | Hepatoma | 5 (0.9) |
| HIV | 10 (1.9) | Castleman's disease | 3 (0.6) |
| Epstein-Barr virus | 5 (0.9) | Acute myelogenous leukemia | 2 (0.4) |
| Hepatitis B | 4 (0.8) | Colon cancer | 2 (0.4) |
| other viral infections | 2 (0.4) | Myelodysplastic Syndrome | 1 (0.2) |
|
| 12 (2.3) | Renal carcinoma | 1 (0.2) |
| Candida albicans | 2 (0.4) | Cholangiocarcinoma | 1 (0.2) |
| Pneumocystis carinii pneumonia | 2 (0.4) | Multiple myeloma | 1 (0.2) |
| Crytococcus neoformans | 2 (0.4) | Thyroid carcinoma | 1 (0.2) |
| Pulmonary aspergillosis | 1 (0.2) |
| 14 (2.7) |
| Candida tropicalis | 1 (0.2) | Subacute thyroiditis | 9 (1.7) |
| Other fungal infections | 4 (0.8) | Drug fever | 3 (0.6) |
|
| 1 (0.2) | Hyperthyroidism | 1 (0.2) |
| Malaria | 1 (0.2) | Necrotizing lymphadenitis | 1 (0.2) |
|
| 154 (29.2) |
Test of the difference of indexes (continuous indexes) in patients with classic FUO of different etiological types.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| No. of cases | 277 | 51 | 31 | 14 | ||
|
| ||||||
| Male | 165 (59.6%) | 20 (39.2%) | 17 (54.8%) | 6 (42.9%) | 8.24 | 0.041 |
| Female | 112 (40.4%) | 31 (60.8%) | 14 (45.2%) | 8 (57.1%) | ||
|
| ||||||
| Yes | 109 (39.4%) | 20 (39.2%) | 13 (41.9%) | 4 (28.6%) | 0.76 | 0.858 |
| No | 168 (60.6%) | 31 (60.8%) | 18 (58.1%) | 10 (71.4%) | ||
|
| ||||||
| Yes | 35 (12.6%) | 8 (15.7%) | 15 (48.4%) | 1 (7.1%) | 27.59 | <0.001 |
| No | 242 (87.4%) | 43 (84.3%) | 16 (51.6%) | 13 (92.9%) | ||
|
| ||||||
| Yes | 66 (23.8%) | 6 (11.8%) | 3 (9.7%) | 8 (57.1%) | 16.32 | <0.001 |
| No | 211 (76.2%) | 45 (88.2%) | 28 (90.3%) | 6 (42.9) | ||
|
| ||||||
| Yes | 9 (3.2%) | 3 (5.9%) | 0 (0.0%) | 0 (0.0%) | 2.66 | 0.447 |
| No | 268 (96.8%) | 48 (94.1) | 31 (100.0%) | 14 (100.0%) | ||
|
| ||||||
| Yes | 25 (9.0%) | 12 (23.5%) | 1 (3.2%) | 6 (42.9%) | 23.96 | <0.001 |
| No | 252 (91.0%) | 39 (76.5%) | 30 (96.8%) | 8 (57.1%) | ||
|
| ||||||
| Yes | 17 (6.1%) | 6 (11.8%) | 5 (16.1%) | 2 (14.3%) | 5.79 | 0.122 |
| No | 260 (93.9%) | 45 (88.2%) | 26 (83.9%) | 12 (85.7%) | ||
|
| ||||||
| Yes | 19 (6.9%) | 12 (23.5%) | 3 (9.7%) | 2 (14.3%) | 14.09 | 0.003 |
| No | 258 (93.1%) | 39 (76.5%) | 28 (90.3%) | 12 (85.7%) | ||
|
| ||||||
| Yes | 30 (10.8%) | 12 (23.5%) | 1 (3.2%) | 0 (0.0%) | 11.25 | 0.010 |
| No | 247 (89.2%) | 39 (76.5%) | 30 (96.8%) | 14 (100.0%) | ||
|
| ||||||
| Yes | 7 (2.5%) | 5 (9.8%) | 2 (6.5%) | 2 (14.3%) | 9.63 | 0.022 |
| No | 270 (97.5%) | 46 (90.2%) | 29 (93.5%) | 12 (85.7%) | ||
|
| ||||||
| Yes | 10 (3.6%) | 9 (17.6%) | 4 (12.9%) | 0 (0.0%) | 18.10 | <0.001 |
| No | 267 (96.4%) | 42 (82.4%) | 27 (87.1%) | 14 (100.0%) | ||
|
| ||||||
| Yes | 1 (0.4%) | 3 (5.9%) | 3 (9.7%) | 0 (0.0%) | 18.41 | <0.001 |
| No | 276 (99.6%) | 48 (94.1) | 28 (90.3%) | 14 (100.0%) | ||
|
| ||||||
| Yes | 9 (3.2%) | 2 (3.9%) | 2 (6.5%) | 0 (0.0%) | 1.39 | 0.708 |
| No | 268 (96.8%) | 49 (96.1%) | 29 (93.5%) | 14 (100.0%) | ||
Test of difference of indexes (classification indexes) in patients with classic FUO of different etiological types.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Age [year, M (P25, P75)] | 55.00 (42.00, 68.00) | 51.00 (40.50, 60.50) | 57.00 (43.50, 67.50) | 42.00 (32.50, 50.75) | 9.34 | 0.025 |
|
| ||||||
| Globulin (g/L, | 31.89 ± 6.95 | 33.20 ± 5.77 | 32.37 ± 7.66 | 33.47 ± 3.50 | 0.44 | 0.725 |
| RBC (× 1012/L, | 3.82 ± 0.72 | 3.38 ± 0.68 | 3.38 ± 0.85 | 3.98 ± 0.67 | 6.97 | <0.001 |
| LDH [U/L, M (P25, P75)] | 219.50 (157.75, 441.48) | 340.00 (198.50, 629.50) | 408.00 (244.45, 867.00) | 191.00 (166.50, 251.58) | 12.37 | 0.006 |
| CRP [mg/L, M (P25, P75)] | 61.90 (20.23, 115.11) | 48.23 (10.21, 130.42) | 112.78 (62.32, 152.64) | 24.94 (8.38, 130.35) | 6.59 | 0.086 |
| PCT [ng/ml, M (P25, P75)] | 0.21 (0.09, 0.77) | 0.26 (0.10, 0.59) | 0.43 (0.19, 1.89) | 0.07 (0.05, 0.12) | 15.69 | 0.001 |
| ESR [mm/H, M (P25, P75)] | 57.00 (29.50, 83.50) | 69.00 (36.00, 94.50) | 70.00 (38.75, 91.00) | 49.00 (26.00, 78.75) | 3.33 | 0.344 |
| Monocyte [× 109/L, M (P25, P75)] | 0.47 (0.31, 0.66) | 0.44 (0.15, 0.70) | 0.71 (0.55, 0.99) | 0.55 (0.41, 0.77) | 12.26 | 0.007 |
| Basophils [× 109/L, M (P25, P75)] | 0.01 (0.01, 0.02) | 0.01 (0.00, 0.02) | 0.01 (0.01, 0.02) | 0.01 (0.00, 0.02) | 0.53 | 0.913 |
| Eosinophils [× 109/L, M (P25, P75)] | 0.04 (0.01,0.10) | 0.02 (0.00,0.10) | 0.03 (0.01,0.12) | 0.02 (0.00,0.06) | 1.67 | 0.645 |
| Lymphocyte [× 109/L, M (P25, P75)] | 0.95 (0.61, 1.41) | 0.79 (0.55, 1.15) | 0.92 (0.61, 1.71) | 1.43 (0.94, 1.61) | 8.51 | 0.037 |
| WBC [× 109/L, M (P25, P75)] | 7.20 (5.45, 10.51) | 8.04 (5.20, 11.39) | 10.27 (6.15, 16.94) | 6.48 (5.52, 11.29) | 3.15 | 0.370 |
| ALP [U/L, M (P25, P75)] | 83.30 (65.50, 119.25) | 92.00 (71.00, 134.00) | 110.60 (96.50, 208.00) | 96.50 (78.75, 128.50) | 9.83 | 0.020 |
| PLT [× 109/L, M (P25, P75)] | 224.00 (172.00, 311.50) | 214.00 (108.00, 303.00) | 200.00 (86.00, 301.50) | 334.00 (159.50, 408.00) | 3.75 | 0.289 |
| ALT [U/L, M (P25, P75)] | 24.00 (13.00, 41.00) | 29.00 (14.00, 53.60) | 21.00 (14.00, 40.00) | 26.00 (21.00, 36.00) | 1.89 | 0.597 |
| AST [U/L, M (P25, P75)] | 26.00 (17.00, 44.00) | 33.50 (23.00, 80.00) | 30.00 (19.00, 53.00) | 17.00 (14.40, 28.00) | 10.21 | 0.017 |
| GGT [U/L, M (P25, P75)] | 46.00 (23.00, 108.00) | 51.00 (27.00, 115.00) | 77.00 (53.00, 196.00) | 33.00 (28.00, 71.00) | 8.70 | 0.033 |
Comparison of five ML models.
|
|
|
|
|
|---|---|---|---|
| RF | 74.4 | 74.4 | 74.4 |
| SVM | 73.4 | 73.4 | 73.4 |
| LightGBM | 75.8 | 75.8 | 75.8 |
| ANN | 70.8 | 70.8 | 70.8 |
| NB | 71.0 | 71.0 | 71.0 |
Figure 3Ranking of importance of characteristics of patients with classic FUO in predicting all types of causes.
Figure 4SHapley Additive exPlanations (SHAP) scores for identifying important features for the prediction of etiological types. (A) Infectious diseases; (B) NIID; (C) neoplastic diseases; and (D) other diseases. Colors indicate whether the value of the feature is high (red) or low (blue).